Leeward Investments LLC MA Has $16.85 Million Position in Laboratory Co. of America Holdings (NYSE:LH)

Leeward Investments LLC MA grew its holdings in Laboratory Co. of America Holdings (NYSE:LH) by 5.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 77,106 shares of the medical research company’s stock after acquiring an additional 3,650 shares during the period. Leeward Investments LLC MA owned 0.09% of Laboratory Co. of America worth $16,845,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of LH. Everett Harris & Co. CA raised its stake in shares of Laboratory Co. of America by 26.1% in the 1st quarter. Everett Harris & Co. CA now owns 23,576 shares of the medical research company’s stock valued at $5,150,000 after acquiring an additional 4,873 shares in the last quarter. American National Bank & Trust Co. VA bought a new position in shares of Laboratory Co. of America in the first quarter valued at approximately $284,000. New Century Financial Group LLC lifted its stake in shares of Laboratory Co. of America by 7.5% in the first quarter. New Century Financial Group LLC now owns 2,495 shares of the medical research company’s stock worth $545,000 after buying an additional 175 shares during the last quarter. AMI Asset Management Corp boosted its holdings in shares of Laboratory Co. of America by 3.0% during the 1st quarter. AMI Asset Management Corp now owns 217,698 shares of the medical research company’s stock worth $47,558,000 after buying an additional 6,340 shares during the period. Finally, Tempus Wealth Planning LLC grew its stake in Laboratory Co. of America by 8.9% in the 1st quarter. Tempus Wealth Planning LLC now owns 1,616 shares of the medical research company’s stock valued at $353,000 after buying an additional 132 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Laboratory Co. of America Trading Up 0.6 %

Shares of LH traded up $1.13 during trading hours on Thursday, reaching $203.86. The stock had a trading volume of 408,054 shares, compared to its average volume of 597,219. The firm has a 50-day moving average of $202.07 and a 200 day moving average of $212.55. The company has a quick ratio of 0.76, a current ratio of 0.88 and a debt-to-equity ratio of 0.39. The company has a market cap of $17.19 billion, a P/E ratio of 41.02, a P/E/G ratio of 1.52 and a beta of 1.05. Laboratory Co. of America Holdings has a 52 week low of $191.97 and a 52 week high of $234.09.

Laboratory Co. of America (NYSE:LH) last announced its earnings results on Thursday, April 25th. The medical research company reported $3.68 EPS for the quarter, topping the consensus estimate of $3.48 by $0.20. The firm had revenue of $3.18 billion for the quarter, compared to the consensus estimate of $3.12 billion. Laboratory Co. of America had a net margin of 3.52% and a return on equity of 14.68%. The business’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period last year, the company posted $3.82 EPS. On average, sell-side analysts expect that Laboratory Co. of America Holdings will post 14.87 earnings per share for the current fiscal year.

Laboratory Co. of America Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, June 12th. Shareholders of record on Tuesday, May 28th were given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.41%. The ex-dividend date of this dividend was Friday, May 24th. Laboratory Co. of America’s dividend payout ratio (DPR) is currently 57.95%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Truist Financial lowered their price objective on shares of Laboratory Co. of America from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Argus upgraded shares of Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 price objective on the stock in a report on Monday, March 25th. StockNews.com cut shares of Laboratory Co. of America from a “buy” rating to a “hold” rating in a research note on Tuesday, June 4th. Barclays lowered their price target on Laboratory Co. of America from $234.00 to $213.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Finally, Robert W. Baird reduced their price objective on Laboratory Co. of America from $255.00 to $244.00 and set an “outperform” rating for the company in a research report on Friday, April 26th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, Laboratory Co. of America presently has an average rating of “Moderate Buy” and an average target price of $241.86.

Insider Transactions at Laboratory Co. of America

In other news, CAO Peter J. Wilkinson sold 2,439 shares of the stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $204.33, for a total transaction of $498,360.87. Following the completion of the transaction, the chief accounting officer now directly owns 2,087 shares in the company, valued at approximately $426,436.71. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, CAO Peter J. Wilkinson sold 2,439 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $204.33, for a total transaction of $498,360.87. Following the sale, the chief accounting officer now owns 2,087 shares in the company, valued at approximately $426,436.71. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kerrii B. Anderson sold 250 shares of the firm’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $200.10, for a total transaction of $50,025.00. Following the completion of the transaction, the director now directly owns 15,722 shares of the company’s stock, valued at $3,145,972.20. The disclosure for this sale can be found here. Insiders sold 4,939 shares of company stock valued at $1,021,078 in the last ninety days. 0.85% of the stock is currently owned by corporate insiders.

Laboratory Co. of America Profile

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).